Atopic Dermatitis

NYC allergists discuss tapinarof's 80-day treatment-free interval, ruxolitinib's box warning hurdles, and more.

Moderator Greg Bensch and a panel of allergists discuss itch control, access barriers, and guideline gaps shaping newer AD topicals in this clinical forum.

How should clinicians choose atopic dermatitis treatments? Harrison Nguyen, MD, discusses personalized therapy and when to escalate care.

Organon reports pooled phase 3 data showing tapinarof cream (VTAMA) improved atopic dermatitis severity across pediatric and adult age groups by Week 8.

Walter Liszewski, MD, discusses how dermatologists can personalize atopic dermatitis treatment using biologics, JAK inhibitors, and topicals.

Sanofi has discontinued development of OX40L-targeting amlitelimab for atopic dermatitis, following the heels of Kyowa Kirin's similar rocatinlimab discontinuation.

Jason Hawkes, MD, explains how new biologics and targeted therapies are advancing precision medicine and improving personalized care in atopic dermatitis.

Experts unpack where new eczema creams fit, and why insurance hurdles and steroid fear keep patients from faster itch relief.

Jason Hawkes, MD, explains how targeted therapies are advancing precision medicine and reshaping personalized care for atopic dermatitis.

Most newer nonsteroidal topical options are now approved for children as young as 2 years. Linda Stein Gold, MD, discusses adherence and misconceptions of pediatric AD.

New topical mechanisms introduce more ways to control pediatric AD without the sting, burn, or long-term steroid concerns that limit adherence, Linda Stein Gold, MD, says.

New secondary endpoint analyses from Phase 3 LATITUDE PsO 3001 and 3002 reveal high rates of clearance on high-impact areas.

These positive topline findings highlight the investigational TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis.

In this SDPA Conference interview, Zirwas continues his discussion of increasing environmental impacts on rates of atopic dermatitis.

Matthew Zirwas, MD, speaks in this SDPA interview about evidence for atopic dermatitis being more of an environmental disease than a genetic one.

New phase 2 findings on tralokinumab, from TRAPEDS-1, show favorable results in children 6 - 11 years with atopic dermatitis.

The supplemental New Drug Application for Arcutis’ roflumilast cream 0.05% (Zoryve) is for mild to moderate atopic dermatitis in those down to 3 months.

This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.

Matthew Zirwas, MD, on why adult-onset atopic dermatitis is the most undertreated condition in dermatology and how diagnostic criteria are driving years of delayed care.

The topic of precision medicine in dermatology is explored in this segment of Bunick's interview at RAD 2026.

This interview at RAD highlights FDA-approved therapies in the atopic dermatitis treatment armamentarium.

Matthew Zirwas, MD, explains why topical JAK inhibitors represent a clinical turning point for hand eczema.

Matthew Zirwas, MD, on using dupilumab and lebrikizumab to guide patch testing decisions and the 2 most missed allergens in eczematous disease.

Siegfried discusses some of the most notable highlights of her session at the RAD 2026 conference regarding clinical pearls in dermatology.

This segment of Lio's RAD Conference interview in Nashville highlights the growing number of therapeutics and an increasingly personalized approach.